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Hepatitis B is a vaccine preventable disease and is notifiable in South Africa. Hepatitis B
vaccination was incorporated into the Expanded Programme on Immunisation in South
Africa in 1995. We used a convenience sample from community-based febrile rash surveil-
lance in 2013 to estimate hepatitis B sero-prevalence. Of samples serologically negative for
acute measles infection, 450 samples spanning nine provinces of South Africa were tested
for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepati-
tis B core antibody (anti-HBc).
Results
Two children (2/450; 0.4%) tested positive for HBsAg. Three hundred and three children
(67.3%) had evidence of vaccine induced immunity. Vaccine induced immunity was present
in 80.2% of 1–5 year olds, but only 60.3% of 10–14 year olds. Natural immunity, indicating
exposure to circulating hepatitis B, was present in 13/450 (2.9%) children.
Conclusion
Chronic hepatitis B in South African has decreased in prevalence from highly endemic levels
prior to vaccine introduction to approximately 0.4% in this sample, demonstrating impact of
a successful vaccination programme 18 years after introduction. Decreased vaccine-
induced immunity with increasing age may reflect waning antibody titres over time.
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Introduction
Hepatitis B is a vaccine preventable disease and is notifiable in South Africa. There is no active
national surveillance for hepatitis B. We estimated hepatitis B seroprevalence in South African
children using residual sera from febrile rash surveillance.
Prior to vaccine introduction, South Africa was considered a country of high hepatitis B
endemicity, defined as�8% prevalence for hepatitis B surface antigen (HBsAg) in the general
population[1]. Rates of 5–16% for hepatitis B surface antigen were seen in rural black men,
with lower rates in females, urban populations and other ethnic groups [2–5]. In the late 1980s
in Kwazulu-Natal province, rates of 18.5% in rural and 10% in urban black children were
reported, with rates of 2.5% in urban children under 6 years [6], while rates of 1% were
reported in urban children 1–19 years of age in Soweto, Gauteng province [7]. Areas of the
Eastern Cape in the 1990s had prevalence rates of 10% in children less than 6 years old [8].
Paediatric hepatitis B in South Africa in the pre-vaccine era was reported to be mostly due
to horizontal transmission in childhood rather than vertical transmission from mother to
child. Modes of horizontal transmission are not well defined but may result from exposure
amongst children to infectious saliva or open sores amongst other postulated mechanisms [3,
6, 9–12].
Hepatitis B vaccination was incorporated into the routine Expanded Programme on Immu-
nisation in South Africa in 1995, administered at 6, 10 and 14 weeks of age. An 18-month
booster dose was later added in 2015, as part of a hexavalent preparation [13]. The World
Health Organisation and United Nations International Children’s Emergency Fund (UNI-
CEF) estimates of third dose hepatitis B vaccine coverage range from 66–85% from 2006 to
2017 [14]. A birth dose was not part of the South African immunisation schedule during this
period. Since universal hepatitis B vaccine introduction into infant schedules, prevalence of
chronic hepatitis B infection, measured by presence of hepatitis B surface antigen has
decreased globally [15]. High HIV prevalence rates in South Africa may, however, influence
rates of vertical transmission to infants or chronic carriage amongst children[16, 17].
In 2012, HIV prevalence in South Africa was estimated at 12.2% overall, with prevalence of
2.4% in children 2–14 years [18]. In studies published since 2000, HBsAg prevalence in South
African adults living with HIV has been reported as 0.4–9.4% in HIV clinics [19–28] and up to
22.9% using hospital-based residual sera [29–31]. In antenatal clinics, rates of HBsAg in preg-
nant women ranged from 0.4–5.8% in HIV-uninfected women and 2.1–7.4% in HIV-infected
women [32–35]. Regarding influence of HIV on hepatitis B vertical transmission from mother
to child, Chotun et al found 0.3% of infants born to HIV-infected women positive for HBsAg,
dropping to 0.2% on follow up [16]. Hoffman et al found 0.5% of infants born to HIV infected
mothers positive for HBsAg [17]. Regarding hepatitis B seroprevalence in children, Jooste et al
screened South African HIV-infected children and adolescents and found 0.8% positive for
HBsAg [36]. In outpatient clinics, Simani et al found HBsAg prevalence of 0.4% in children
under two years old (with higher prevalence of 2.7% in HIV-infected children) [37].
Community-based rash surveillance is used as a detection system for possible measles infec-
tion. Serum samples of children who have rash and fever together with cough, coryza or con-
junctivitis are sent to the National Institute for Communicable Disease for measles serology.
Approximately 7000 samples are tested annually, of which usually less than 50 are positive for
measles IgM. The remaining samples are from children with acute rash illness other than mea-
sles. Rash in children has many aetiologies including viral (measles, rubella, ECHO, coxsackie,
parvovirus B19, herpesvirus 6 and others), bacterial and rickettsial infections and other non-
infectious causes. Rash therefore may affect any sector of the population including multiple
ethnic, socioeconomic and demographic groups.
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In this study, hepatitis B infection, exposure and protection was measured in children less




Of 7107 rash samples collected in 2013, 450 samples were sequentially selected from children
less than 15 years of age that tested negative for measles and rubella IgM. Samples with insuffi-
cient serum volume (<600μl) were excluded. Hepatitis B surface antigen (HBsAg), hepatitis B
surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc) were tested. HBsAg pos-
itive samples were further tested for e antigen (HBeAg), antibodies to e antigen (anti-HBe),
viral load and genotyping.
Laboratory tests
HBsAg and anti-HBc were run on the Architect instrument (Abbott, Germany) and values
equal to or greater than 1.00 Sample/Cutoff (S/CO) were considered positive. Anti-HBs titres
(Architect, Abbott, Germany) were reported as milli-international units per ml (mIU/ml)
according to WHO international reference standard (Hollinger and Dreesman, 1986). Samples
equal to or greater than 10mIU/ml were considered positive for anti-HBs. Samples positive for
HBsAg were tested for HBeAg and anti-HBe (Architect, Abbot, Germany) with cutoff at 1.00
S/CO.
Hepatitis B viral load was performed on HBsAg positive samples using the COBAS Ampli-
Prep/COBAS TaqMan HBV Test, v2.0, quantitative assay (Roche Molecular Systems, New Jer-
sey, USA). Sequencing was performed on the polymerase region (nucleotides 2624–1240),
overlapping the complete S region (nucleotides 2848–2835) using BigDye Terminator v3.0
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) on the ABI
3130XL Genetic Analyzer (Applied Biosystems) [38]. Neighbour-joining phylogenetic analysis
with a bootstrap of 1000 replicates was conducted using Molecular Evolutionary Genetics
Analysis (MEGA 5)[39].
Data analysis
Results are reported as indicative of chronic infection (HBsAg positive), vaccine induced
immunity (HBsAg negative, anti-HBs positive,anti-HBc negative) or natural exposure (HBsAg
negative, anti-HBc positive).
Sample size
Sample size calculation was conducted using Open-Epi software. Based on an anticipated 2%
prevalence of HBsAg positive samples, with a 99% confidence level, confidence limits of +/-
2% and a design effect of 1, a minimum sample size of 350 samples was needed. The study was
not powered to estimate hepatitis B prevalence stratified by age group or by province.
Ethics
This study was approved by the University of Witwatersrand Human Research Ethics commit-
tee (clearance certificate M140857). Subjects were not required to give informed consent as
samples had been collected during routine febrile rash surveillance and were anonymized for
this study.
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Results
Of 450 samples selected, 47% were females and 53% were males, with a median age of 5 years.
Ages of included children were 11 aged 0–11 months, 217 aged 1–5 years, 174 aged 6–10 years
and 48 aged 11–14 years (2.4%, 48%, 38.7% and 10.7% respectively). Provincial distribution of
samples included Mpumalanga 14% (n = 65) Eastern Cape 13% (n = 59), North West Province
13% (n = 58), Northern Cape 12% (n = 55), KwaZulu Natal 11% (n = 51), Free State 10%
(n = 43), Limpopo 10% (n = 47), Gauteng 9% (n = 42) and Western Cape 7% (n = 30).
HBsAg was positive in two children, 0.4% (2/450) of the sample, a 2 year-old from Ehlan-
zeni in Mpumalanga province (HBeAg positive, viral load 4.6log10copies/ml) and a 12-year-
old from Ethekwini Metro in KwaZulu-Natal (HBeAg negative, anti-HBe positive, viral load
2.6 log10copies/ml). Both children were positive for anti-HBc and both samples were genotype
A1.
Vaccine induced immunity (individuals positive for anti-HBs with negative anti-HBc [40])
was high in children under 1 year (81.8%) and 1–5 years (80.2%) but lower in older age groups
(60.3% in 6–10 year olds and 31.3% in 11–15 year olds (Table 1). Overall, 2.9% of children
(13/450) had evidence of natural exposure (anti-HBc) to hepatitis B, implying they had been
exposed to circulating HBV at some time. Of the 450 samples tested, 132 (29.3%) had no sero-
logical markers positive, indicative of either no exposure to HBV, no exposure to hepatitis B
vaccine, or perhaps prior vaccine induced immunity which may have waned with time.
Discussion
Our finding of 0.4% prevalence of hepatitis B infection in children under 15 years of age adds
an estimate of burden of infection in the post vaccine era. While other studies have focused on
targeted clinics (antenatal, HIV, immunisation, outpatient clinics) or used hospital-based
residual sera, we have studied a community-based population. We found two cases positive for
HBsAg, which may reflect either horizontally or vertically acquired infections.
Vaccine induced immunity was highest in infants and young children, decreasing in older
age groups.
Age dependent decreases in rates of vaccine induced immunity could imply absence of vac-
cination, biological non-response to vaccine or waning of immunity. Reduction in immunity
as age increases has been previously reported. [41–45]. Protection against infection may
endure despite waning of anti-HBs titres, as immunologic memory produces anamnestic
responses to boosters [45, 46]. Anti-HBs prevalence is therefore not a reliable indicator of
community vaccination coverage or immunity to hepatitis B infection and should be inter-
preted with caution.
HIV infection was not tested in our samples, due to ethical sensitivities. We therefore can-
not analyse whether carriage rates of hepatitis B in children differ in those who are HIV
infected or exposed from those who are HIV uninfected. Occult hepatitis B infection was not
investigated. Occult hepatitis B, usually considered as detectable hepatitis B deoxyribonucleic
acid (DNA) but undetectable HBsAg, has previously been reported in both HIV negative and
HIV positive adults [20, 29, 30, 34, 35, 47] and HIV exposed infants [16, 17, 48] in South
Africa. In patients with occult hepatitis B, antibody against Hepatitis B core antigen is often
detected. The clinical implications of occult hepatitis B infection for patient prognosis thus
remain obscure [49]. HBsAg remains the most frequently used test for prevalence in most epi-
demiological surveys and allows comparisons between countries and over different time
periods.
Relatively few samples were included from patients under one year of age, due to insuffi-
cient residual serum volume from most infant samples. Infant samples can give information
Hepatitis B seroprevalence in South Africa
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regarding suspected vertical transmission, although horizontal transmission may also occur in
the first year of life. Infant sampling may also be confounded by maternal antibody levels.
Babies born to HBsAg-positive mothers who do not become infected may be positive for anti-
HBc for up to 24 months after birth from passively acquired maternal antibody [49].
We are unable to comment on rural versus urban origin of individuals included due to lim-
ited information. Prior to introduction of universal hepatitis B vaccination in South Africa,
rates in urban areas were lower than in rural areas. Our samples may be biased to children
originating from urban areas, who would be more likely to seek health care during febrile rash
illness. Rural and urban districts actively participate in febrile rash surveillance, however, and
are required to meet similar targets for surveillance adequacy. The private sector may be
under-represented as surveillance officers are employed by national and provincial depart-
ments of health rather than private organizations. Surveillance officers are, however, tasked
with active surveillance in both public and private institutions. The study was not powered to
analyse whether differences existed in rates of HBsAg carriage per province. Increasing the
sample size to include representative numbers of samples from each province could be per-
formed in future to give geographic estimates of disease prevalence.
Previous studies on hepatitis B in the post- vaccination era have largely been conducted in
localized health-care facilities or from tertiary referral centres, with the majority of patients
drawn from one or two provinces. A strength of our study is the national distribution of sam-
ples included. Despite the non-measles febrile rash illness of our participants, they are unlikely
to be drawn from particularly high or low risk groups for vaccination completion as viral rash
illness is not vaccine preventable and patients with rash are therefore a “biologically arbitrary”
selection. Since febrile rash surveillance is performed in a similar fashion by most WHO mem-
ber states, this study design represents a convenience sample that could be replicated in other
countries in order to inform regional prevalence and immunity figures. Representivity of rash
surveillance samples may be skewed in countries with routine rubella immunisation, where
febrile rash samples may be biased towards unvaccinated children. Rubella immunisation is
not currently part of the South African routine immunisation schedule.
In conclusion, we report HBsAg prevalence of 0.4% in South African children from a
period in which the Expanded Programme on Immunisation schedule included three primary
doses but no booster or birth dose. While studies with active community-based random sam-
pling are the gold standard for seroprevalence studies, residual samples from febrile rash sur-
veillance are a low-cost proxy that can be repeated annually and can offer insights regarding
disease trends over time. Febrile rash surveillance samples could also be used to study sero-
prevalence of other diseases.
Table 1. Hepatitis B serology in residual sera from patients with febrile rash illness, by age group.
Age groups (n)
0-11months 1-5years 6-10years 11-14years Total
n % n % n % n % n %
Infected (HBsAg+) 0 0.0 1 0.5 0 0.0 1 2.1 2 0.4
Vaccine Immunity (anti-HBs+ and anti-HBc-) 9 81.8 174 80.2 105 60.3 15 31.3 303 67.3
Natural exposure (anti-HBc+) 1 9.1 5 2.3 6 3.4 1 2.1 13 2.9
No evidence of natural exposure or vaccine immunity (HBsAg-, anti-HBs- and anti-HBc-) 1 9.1 37 17.1 63 36.2 31 64.6 132 29.3
Total 11 100.0 217 100.0 174 100.0 48 100.0 450 100.0
HBsAg hepatitis B surface antigen; anti-HBs Hepatitis B surface antibody; anti-HBc Hepatitis B core antibody; + positive
- negative; n number. Percentages shown in darker shade with totals reflecting column totals.
https://doi.org/10.1371/journal.pone.0217415.t001
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